奥贝胆酸 说明书

Developed by Intercept Pharmaceuticals in the United States, its compound patent was applied for in the United States in 2001 with the patent number US7138390. It has not yet applied for a compound patent in China. Obeticholic acid is the first drug developed to treat cholestatic liver disease in 20 years, targeting patients who have not responded adequately to or cannot tolerate ursodeoxycholic acid.

Generic name: obeticholic acid Product name: Obetix All names: Obeticholic acid,Obeticholic acid,Obetix,Ocaliva

Obetix indications: Obeticholic acid combined with ursodeoxycholic acid (UDCA) is indicated for adult patients with primary biliary cholangitis (formerly known as primary biliary cirrhosis, PBC) who have an inadequate response to UDCA, or as monotherapy for adults with primary biliary cholangitis who are intolerant to UDCA.   Obetix usage and dosage: For oral tablets, the initial recommended dose is 5 mg once daily. Based on clinical response, treatment is gradually titrated to 10 mg (once daily) over 6 months.   Use of Obetix in Special Populations: Not suitable for patients with complete intestinal obstruction.